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Abstract: Purpose
This study investigated metabolic benefits of protein hydrolysates from the macroalgae
Palmaria palmata  , previously shown to inhibit dipeptidylpeptidase-4 (DPP-4) activity
in vitro  .
Methods
Previously, Alcalase/Flavourzyme-produced  P. palmata  protein hydrolysate (PPPH)
improved glycaemia and insulin production in streptozotocin-induced diabetic mice.
Here the PPPH, was compared to alternative Alcalase, bromelain and Promod derived
hydrolysates and an unhydrolysed control. All PPPH’s underwent simulated
gastrointestinal digestion (SGID) to establish oral bioavailability. PPPH’s and their
SGID counterparts were tested in pancreatic, clonal BRIN-BD11 cells to assess their
insulinotropic effect and associated intracellular mechanisms. PPPH actions on the
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
incretin effect were assessed via measurement of DPP-4 activity, coupled with GLP-1
and GIP release from GLUTag and STC-1 cells, respectively.  Acute  in vivo  effects of
Alcalase/Flavourzyme PPPH administration on glucose tolerance and satiety were
assessed in overnight-fasted mice.
Results
PPPH’s (0.02-2.5 mg/ml) elicited varying insulinotropic effects (p<0.05–0.001). SGID of
the unhydrolysed protein control, bromelain and Promod PPPH’s retained, or
improved, bioactivity regarding insulin secretion, DPP-4 inhibition and GIP release.
Insulinotropic effects were retained for all SGID-hydrolysates at higher PPPH
concentrations. DPP-4 inhibitory effects were confirmed for all PPPH’s and SGID
counterparts (  p  <0.05–0.001). PPPH’s were shown to directly influence the incretin
effect via upregulated GLP-1 and GIP (  p  <0.01–0.001) secretion  in vitro  , largely
retained after SGID. Alcalase/Flavourzyme PPPH produced the greatest elevation in
cAMP (p<0.001, 1.7-fold), which was fully retained post-SGID. This hydrolysate elicited
elevations in intracellular calcium (  p  <0.01) and membrane potential (  p  <0.001). In
acute  in vivo  settings, Alcalase/Flavourzyme PPPH improved glucose tolerance (  p
<0.01–0.001) and satiety (  p  <0.05–0.001).
Conclusion
Bioavailable PPPH peptides may be useful for the management of T2DM and obesity.
Suggested Reviewers: Dagmar Stengel, PhD
Botany and Plant Science, NUIG: National University of Ireland Galway
dagmar.stengel@nuigalway.ie
Has expertise in seaweed and plant sciences and extraction of components from
Palmaria palmata seaweed.
Chao Zhao, PhD
Agriculture Forestry and Fisheries Research Council Secretariat Tsukuba Office
Department of Research and Information: Norin Suisan Kenkyu Joho Sogo Center
zhchao@live.cn
Has expertise in antidiabetic effects of seaweed in diabetic animal models
Yoav D Livney, PhD
Professor, Technion Israel Institute of Technology
livney@technion.ac.il
Expertise in proteins from macroalgae for food applications
Elis Lima, PhD
University of the Azores Department of Agricultural Sciences: Universidade dos Acores
Departamento de Ciencias Agrarias
elis@uac.pt
This author has recently published articles on the bioactivity of macroalgae.
Yang Ruijin, PhD
Jiangnan University School of Food Science and Technology
yrj@jiangnan.edu.cn
These authors have extensive experience in isolation of proteins and hydrolysates
form seaweeds and have recently published in this same area.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Title: Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ 
   
1McLaughlin, C. M.; 2,3Harnedy-Rothwell, P. A.; 1Lafferty, R. A.; 1Sharkey, S.; 1Parthsarathy, 
V.; 3Allsopp, P. J.; 3McSorley, E. M.; 2,3FitzGerald, R. J. and 1O’Harte, F.P.M. 
1School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, Co. Derry, 
BT52 1SA, Northern Ireland. 
2Department of Biological Sciences, University of Limerick, Castletroy, Limerick, Ireland.  
3Health Research Institute (HRI), University of Limerick, Limerick, Ireland.4Nutrition 
Innovation Centre for Food and Health, School of Biomedical Sciences, Ulster University, 
Cromore Road, Coleraine, Co. Derry, BT52 1SA, Northern Ireland. 
Key words: Antidiabetic, Dipeptidylpeptidase-4, Dulse, Incretin secretion, Palmaria palmata, 
Protein hydrolysate, Type 2 diabetes.  
Character count: 49,519 (Including abstract, references, tables and legends) 
Corresponding author 
Prof. Finbarr O’Harte 
School of Biomedical Sciences 
Ulster University 
Coleraine, BT52 1SA 
Co. Derry 
Northern Ireland. 
T: [+44 (0)28 70 124853]   
E: [fpm.oharte@ulster.ac.uk]  
W: www.ulster.ac.uk /  
W: https://www.ulster.ac.uk/faculties/life-and-health-sciences/schools/biomedical-sciences 
Click here to access/download;Manuscript;P. palmata - Eur J
Nut Revised May 2021.docx
Manuscript




This study investigated metabolic benefits of protein hydrolysates from the macroalgae 3 
Palmaria palmata , previously shown to inhibit dipeptidylpeptidase-4 (DPP-4) activity in vitro. 4 
Methods 5 
Previously, Alcalase/Flavourzyme-produced P. palmata protein hydrolysate (PPPH) improved 6 
glycaemia and insulin production in streptozotocin-induced diabetic mice. Here the PPPH, was 7 
compared to alternative Alcalase, bromelain and Promod derived hydrolysates and an 8 
unhydrolysed control. All PPPH’s underwent simulated gastrointestinal digestion (SGID) to 9 
establish oral bioavailability. PPPH’s and their SGID counterparts were tested in pancreatic, 10 
clonal BRIN-BD11 cells to assess their insulinotropic effect and associated intracellular 11 
mechanisms. PPPH actions on the incretin effect were assessed via measurement of DPP-4 12 
activity, coupled with GLP-1 and GIP release from GLUTag and STC-1 cells, respectively.  13 
Acute in vivo effects of Alcalase/Flavourzyme PPPH administration on glucose tolerance and 14 
satiety were assessed in overnight-fasted mice.  15 
Results 16 
PPPH’s (0.02-2.5 mg/ml) elicited varying insulinotropic effects (p<0.05–0.001). SGID of the 17 
unhydrolysed protein control, bromelain and Promod PPPH’s retained, or improved, 18 
bioactivity regarding insulin secretion, DPP-4 inhibition and GIP release. Insulinotropic effects 19 
were retained for all SGID-hydrolysates at higher PPPH concentrations. DPP-4 inhibitory 20 
effects were confirmed for all PPPH’s and SGID counterparts (p<0.05–0.001). PPPH’s were 21 
shown to directly influence the incretin effect via upregulated GLP-1 and GIP (p<0.01–0.001) 22 
secretion in vitro, largely retained after SGID. Alcalase/Flavourzyme PPPH produced the 23 
3 
greatest elevation in cAMP (p<0.001, 1.7-fold), which was fully retained post-SGID. This 1 
hydrolysate elicited elevations in intracellular calcium (p<0.01) and membrane potential 2 
(p<0.001). In acute in vivo settings, Alcalase/Flavourzyme PPPH improved glucose tolerance 3 
(p<0.01–0.001) and satiety (p<0.05–0.001).  4 
Conclusion 5 


















Introduction  1 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder of complex aetiology characterised 2 
by a deficiency, and/or dysfunction of endogenous insulin and glucagon production [1]. In 3 
diabetes, loss of insulin-producing pancreatic beta-cell mass [2], is accompanied by 4 
dysfunction of glucagon-producing alpha-cells, which fail to respond to the normal suppressive 5 
effects of glucose and insulin, leading to hyperglucagonaemia [3]. Best-estimates state that 6 
there are around 463 million adults globally living with diabetes, projected to rise to 700 7 
million by 2045 [4], with T2DM representing ~90% of cases. The economic burden of diabetes 8 
on global healthcare systems is considerable, with a minimum of $760 billion USD attributed 9 
to spending on the disease in 2019, equating to 10% of global adult healthcare costs [4].  An 10 
important factor in this spending arises from costs amassed from treatment of microvascular 11 
(retinopathy, nephropathy, and neuropathy) and macrovascular (coronary artery disease, 12 
stroke, and peripheral vascular disease) complications [5].  Preventative strategies, coupled 13 
with earlier diagnosis and novel treatments, have the potential to reduce the occurrence of these 14 
complications [6].  15 
Lifestyle interventions such as increased physical activity and improved, nutritionally 16 
balanced diets are considered first-line options in the prevention and treatment of T2DM [7,8]. 17 
While high-quality dietary protein is an integral part of any such diet [9], it has also been 18 
established that a high-protein diet can lower postprandial blood glucose in T2DM and improve 19 
overall glucose and lipid metabolism [10,11]. Beyond dietary protein, protein hydrolysates, 20 
peptides and single amino acids can beneficially regulate glycaemia, with the magnitude of 21 
response differing significantly depending on the primary sequence of peptides and specific 22 
amino acids generated following digestion [12,13].  23 
Mechanisms determining glycaemic improvements of various protein hydrolysates have 24 
been established, highlighting the importance of inhibitory actions on the ubiquitous enzyme 25 
5 
 
dipeptidylpeptidase-4 (DPP-4) [14-18]. DPP-4 inhibition has become a staple of diabetes 1 
management, with a plethora of drugs now available since the approval of sitagliptin (Januvia®) 2 
in 2006 [19]. Success of DPP-4 inhibition lies in the preservation of the “incretin effect”, which 3 
promotes a rise in plasma insulin following food intake [20]. The rise in plasma insulin not 4 
only reflects a response to increased postprandial glucose, but approximately 50% of the 5 
overall insulinotropic response is attributed to the release of two gut-derived hormones, 6 
namely: glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide 7 
(GIP) [20].  Both GLP-1 and GIP are inactivated following N-terminal dipeptide removal by 8 
DPP-4 [19]. Furthermore, DPP-4 resistant GLP-1 receptor agonists (incretin mimetics) have 9 
also been developed and are widely prescribed for T2DM management [21-23].  10 
It has recently been uncovered that, beyond DPP-4 inhibition, protein hydrolysates from 11 
underutilised marine sources, such as blue whiting, boarfish and salmon skin, can directly 12 
influence glycaemia through improved insulin production and secretion coupled with 13 
upregulated GLP-1 secretion in both in vitro [24-26] and in vivo settings [25,27]. The present 14 
study has sought to establish whether crude hydrolysates of the macroalgae Palmaria palmata 15 
can replicate the effects of piscine-derived protein hydrolysates.  16 
P. palmata (dulse) has become popular as a foodstuff due to its relatively high protein 17 
content [28], in addition to being a potential source of biofunctional proteinaceous and 18 
antioxidant ingredients [29-31]. Notably, both crude hydrolysates of P. palmata [32] and 19 
isolated peptides from this source have demonstrated an ability to inhibit DPP-4 in vitro [33]. 20 
Furthermore, twice daily, chronic administration of a crude P. palmata protein hydrolysate, 21 
Alcalase/Flavourzyme PPPH, has been shown to improve glycaemic control in streptozotocin-22 
induced diabetic mice [34]. Thus, the present study aims to employ a number of established 23 
screening methods to uncover the specific mechanisms responsible for the positive glycaemic 24 
effects of PPPH’s and identify the hydrolysate which shows greatest anti-diabetic potential. 25 
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Materials and Methods  1 
Materials and chemicals 2 
H-Gly-Pro-AMC (7-amino-4–methyl coumarin) and Diprotin A were obtained from Bachem 3 
Feinchemikalien (Bubendorf, Switzerland). Promod 144 MG provided by Biocatalysts Ltd. 4 
(Cardiff, Wales, UK). HPLC grade water and acetonitrile from VWR International (Dublin, 5 
Ireland) and trinitrobenzenesulphonic acid (TNBS) reagent was from Medical Supply Co Ltd. 6 
(Dublin, Ireland). Calcium chloride dihydrate (CaCl2×2H2O), D-glucose, HEPES, 7 
hydrochloric acid (HCl), magnesium sulphate (MgSO4×7H2O), potassium dihydrogen 8 
orthophosphate (KH2PO4), potassium chloride (KCl), sodium bicarbonate (NaHCO3) and 9 
sodium chloride (NaCl) were purchased from BDH Chemicals Ltd. (Poole, Dorset, UK). Foetal 10 
bovine serum (FBS), Hank's buffered saline solution (HBSS 10X stock), penicillin–11 
streptomycin (0.1 g/l), RPMI-1640 culture media, Dulbecco's modified Eagle's medium 12 
(DMEM) containing high glucose and trypsin/EDTA (10X) were obtained from Gibco Life 13 
Technologies Ltd. (Paisley, Strathclyde, UK). Radio-labelled sodium iodide (Na125I, IMS 100 14 
mCi/ml stock) was from Perkin Elmer (Buckinghamshire, UK). Rat insulin standard was from 15 
Novo Industria, Copenhagen, Denmark. All other reagents including DPP-4, from porcine 16 
kidney (≥10 units/mg protein), Alcalase® 2.4 L and Flavourzyme® 500 L supplied by Sigma 17 
Chemical Company Ltd. (Wicklow, Ireland). Air-dried milled (5 mm) P. palmata sample was 18 
purchased from Irish Seaweeds Ltd., Belfast, Co. Antrim, N. Ireland. The macroalgae was 19 
further milled with a Cyclotec™ Mill (1 mm screen, FOSS Tecator AB, Hoganas, Sweden) 20 
and stored at RT. 21 
 22 
Preparation of crude aqueous soluble protein extracts 23 
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Crude aqueous and alkaline soluble protein extracts were prepared using the method described 1 
previously [32]. Milled P. palmata powder was suspended at a mass:volume ratio of 1:20 2 
((w/v), 1 kg:20.0 l) and gently agitated at room temperature for 3 h. The supernatant containing 3 
the aqueous soluble protein was acquired following centrifugation at 4,190 x g (Sorvall RC6 4 
Plus, Fisher Scientific, Dublin, Ireland) for 15 min at RT. The pellet was resuspended in 0.12 5 
M NaOH (1:15 (w/v)) and gently agitated for 1 h at RT and supernatant containing the alkaline 6 
soluble protein was acquired following centrifugation. The pellet was subjected to a second 7 
alkaline extraction, and both supernatants combined. A double isoelectric precipitation step 8 
was utilised to semi-purified and concentrated aqueous (pH 2.5) and alkaline (pH 4.0) soluble 9 
protein components. The precipitated protein pellets obtained following the second isoelectric 10 
precipitation were resuspended in dH2O to a protein concentration of ~ 2.4% (w/v) and 11 
combined. Protein concentration was determined by the modified Lowry protein quantification 12 
method as described previously [35]. Samples were analysed in triplicate.  13 
 14 
Enzymatic hydrolysis of macroalgal proteins and simulated gastrointestinal 15 
digestion 16 
Macroalgal protein was hydrolysed as described previously [32]. A 2% (w/v) protein solution 17 
was preheated to 50°C and adjusted to pH 7.0 and hydrolysed with Alcalase 2.4 L, Alcalase 18 
2.4 L and Flavourzyme 500 L, bromelain and Promod 144 MG at an enzyme:substrate (E:S) 19 
ratio of 1:100 (w/w or v/w) for 4 h at 50°C. The reaction was maintained at pH 7.0 using a pH-20 
stat (842 Titrando, Metrohm, Switzerland) and enzyme inactivated by heating at 90°C for 20 21 
min. A control protein sample, containing no proteolytic enzyme, was treated in the same 22 
manner. All samples were subsequently freeze-dried (FreeZone 18L, Labconco, MO, USA) 23 
and stored at -20oC.  24 
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To assess oral bioavailability, PPPH’s were subjected to simulated gastrointestinal 1 
digestion (SGID), described previously [36]. In brief, unhydrolysed protein controls and 2 
hydrolysates were diluted to 2.0% (w/v) protein in water and incubated at 37°C and pH 2 for 3 
90 min with pepsin at an E:S of 1:40 (w/w). The samples were adjusted to pH 7 and subjected 4 
to heat inactivation at 90°C for 20 min. The samples were incubated for a further 150 min at 5 
37°C with Corolase PP (E:S of 1% (w/w)). SGID samples were heat inactivated and all samples 6 
were subsequently freeze-dried and stored at -20°C.  7 
 8 
Physicochemical characterisation of PPPH 9 
The molecular mass distribution profile of the hydrolysates and their SGID samples were 10 
determined by gel permeation-high performance liquid chromatography (GP-HPLC) as 11 
described previously [37]. The amino nitrogen content of PPPH was estimated by the TNBS 12 
method with absorbance readings taken at 350 nm [38]. Samples were analysed in triplicate. 13 
 14 
Insulin secretion studies in clonal pancreatic cells 15 
Insulinotropic effects of PPPH and SGID samples were measured in vitro using clonal 16 
pancreatic BRIN-BD11 cells [39]. BRIN-BD11 cells (1.5 x 105 cells/well) were incubated for 17 
20 min with a range of PPPH concentrations (0.039–2.5 mg/ml) in the presence of 5.6 mM 18 
glucose at 37°C. Following incubation, supernatant (900 µL) was withdrawn and frozen at -19 
20°C until required. Insulin was quantified using a dextran-coated charcoal radioimmunoassay 20 
(RIA), using crystalline rat insulin standard, guinea-pig anti-porcine antiserum (1:30,000 21 
dilution) and 125I-bovine standard (10,000 cpm), described previously [40]. The concentration 22 
of insulin in each sample was determined in duplicate from the prepared insulin standard curve 23 
ranging from 0.039-20 ng/ml.  24 
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Cellular toxicity via MTT assay 1 
To determine cytotoxicity of PPPH and SGID samples on BRIN-BD11 cells, the MTT (3-(4,5-2 
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was employed. A fixed dose 3 
of PPPH was prepared in Krebs Ringer bicarbonate buffer (KRBB) buffer supplemented with 4 
5.6 or 16.7 mM glucose. Upon completion of co-incubation, KRBB was removed and cells 5 
washed with HBSS. Growth media (100 μl) was added to each well of a 96 well plate and 6 
further supplemented with 20 μl of MTT solution (5 mg/ml stock). Plates were incubated for 2 7 
h in a modified atmosphere (95% O2, 5% CO2) tissue culture incubator at 37°C. MTT/growth 8 
media was aspirated and washed for a final time with HBSS. The formazan crystals developed 9 
were then dissolved using 100 μl of DMSO and the plate agitated at RT for 5 min. Plates were 10 
read on a spectrophotometer with absorbance set at 570 nm. 11 
 12 
Quantification of DPP-4 inhibition 13 
DPP-4 inhibition was determined as described previously [33]. Activity was expressed as IC50 14 
values for three independent replicates (n=3). Diprotin A was used as a positive control. 15 
 16 
In vitro GLP-1 secretion from GLUTag cells and GIP secretion from STC-1 cells 17 
In vitro effects of the PPPH and the SGID samples on GLP-1 secretion were measured using 18 
the murine enteroendocrine GLUTag cell line [41], kindly gifted by Prof. Fiona Gribble/Daniel 19 
Drucker. Cells were cultured in high glucose (25 mM) Dulbecco’s Modified Eagle’s Medium 20 
(without glutamine), as described previously [42]. Cells were seeded into 24 well plates (1.5 x 21 
105 cells/well) attaching over 36 h at 37°C. Following a pre-incubation step (1.1 mM glucose 22 
solution in KRBB for 40 min at 37°C), cells were incubated with the PPPH and SGID samples 23 
10 
 
(2.5 mg/ml) prepared in 2 mM glucose followed by 2 h incubation at 37°C. Thereafter, 800 µl 1 
of supernatant was collected and subsequently used to measure total GLP-1 release by ELISA 2 
(Millipore, Hertfordshire, UK) as per manufacturer’s protocol.  3 
STC-1 cells differentiate by secreting satiety and glucose homeostatic hormones such as 4 
CCK, GIP, PYY, GLP-1 and GLP-2 [43]. The experimental procedure was similar to the 5 
GLUTag screening procedure. After 2 h co-incubation, 800 μl of the supernatant was aspirated 6 
and stored at -20°C before quantification using a GIP ELISA (Millipore, Hertfordshire, UK) 7 
as per manufacturer’s protocol. 8 
 9 
Glucose uptake study using differentiated adipocytes 10 
Adipocyte (3T3-L1) cells were obtained from the American Type Culture Collection (ATCC, 11 
Manassas, Virginia, USA). 3T3-L1 cells were seeded in a 96, black-walled, clear bottom plates 12 
(2 x 104 cell/well). Cells were maintained with Dulbecco’s Modified Eagle’s Medium (DMEM) 13 
supplemented with 10% (v/v) heat inactivated FBS. Cells were incubated for a further 2 days 14 
and then differentiated in DMEM containing 10% FBS, 15 μg/mL insulin, 1 μM 15 
dexamethasone and 0.5 mM 3-isobutyl-l-methylxanthine (IBMX). Cells were cultured in 16 
DMEM containing 10% FBS and 15 μg/mL of insulin. Cells were treated with the test sample 17 
(100 µl) or control which were supplemented in glucose-free culture medium containing 150 18 
µg/ml fluorescently tagged 2-deoxyglucose analogue (2-NBDG) and incubated for 20 min. 19 
Plates were centrifuged for 5 min at 400 x G at RT. Supernatant was aspirated, and cells washed 20 
with 200 µl cell-based assay buffer followed by further centrifugation for 5 min. Wash buffer 21 
was removed and 100 µl of cell-based assay buffer was added to all wells and the fluorescence 22 
was read immediately at 485 nm with emission measured at 535 nm using the FlexStation 23 
scanning fluorimeter (Molecular Devices, Sunnyvale, CA, USA).  24 























Effect of PPPH’s (2.5 mg/ml) on changes in membrane potential and intracellular calcium 
concentration [Ca2+] were determined fluorometrically utilising monolayers of BRIN-BD11 
cells and Flex membrane potential and calcium assay kits (Molecular Devices, Sunnyvale, 
CA, USA), as previously described [44]. Assay choice was based on the knowledge that 
increased intracellular [Ca2+] is the primary insulin secretory signal, while cAMP signalling-
dependent mechanisms are also critical for incretin-mediated insulin release [72]. Control 
cultures were 30 mM KCl and 10 mM alanine in the presence of 5.6 mM glucose. 
Fluorometric data was acquired using a FlexStation scanning fluorimeter utilizing an 
integrated fluid transfer workstation (Molecular Devices, Sunnyvale, CA, USA). The effect 
of the PPPH’s subjected to SGID on the production of cAMP was also assessed in BRIN-
BD11 cells. Cells were seeded (1.5 x 105 cells/well) into 24-well plates and incubated 
overnight. Cells were washed with HBSS before incubation (20 min, 37°C) with the PPPH 
(2.5 mg/ml) in the presence of 200 μM IBMX. Culture media was removed, cells lysed and 
the cAMP concentration in lysates was determined using a cAMP detection kit (R&D 
Systems Parameter, Abingdon, UK).  
Acute in vivo effects of a PPPH on glucose tolerance and satiety 
NIH Swiss mice (Harlan UK Ltd., Blackthorne, UK) were employed for acute in vivo 
experiments. Animals (10-12 week old) were maintained in an environmentally controlled 
laboratory at 22 ± 2°C with a 12 h dark and light cycle with ad libitum access to standard rodent 
diet (10% fat, 30% protein and 60% carbohydrate; Trouw Nutrition, Northwich, UK) 
and drinking water. Acute glucose-lowering and insulin releasing properties 
of Alcalase/Flavourzyme PPPH was determined in age-matched groups (n=8) of overnight 
fasted mice, who received an oral gavage of either glucose alone (18.8 mmol/kg body 
weight) or in 11 
24 
12 
combination with PPPH (100 mg/kg bw). Blood glucose was measured using an Ascencia 1 
Contour blood glucose meter (Bayer Healthcare, Newbury, UK) and samples were collected 2 
via tail vein bleed in chilled fluoride/heparin micro-centrifuge tubes (Sarstedt, Numbrecht, 3 
Germany) and centrifuged at 13,000 rpm for 10 min. Plasma was aliquoted and stored at -20°C 4 
until required for insulin determination using a modified dextran-coated charcoal RIA [40].  5 
Satiating effect of Alcalase/Flavourzyme PPPH was assessed in male HsD:Ola TO mice 6 
(10-12 weeks, Envigo, Blackthorn, UK), maintained as above. Animals had ad libitum access 7 
to food for 1 week. This was reduced to 10 h of food availability daily on week 2, with further 8 
reduction to 6 h daily by week 3. Finally, on week 4 and for the duration of the satiety studies, 9 
food availability was strictly maintained at 3 h daily (10.00-13.00 h). Animals (n=8) received 10 
an oral dose of saline (0.9 % NaCl) alone, or in combination with PPPH (100 mg/kg bw) 11 
immediately prior to regular food access at 10.00 h. Food intake was measured at 30 min 12 
intervals up to 180 min.  13 
14 
Statistical analysis 15 
Results were analysed using GraphPad PRISM 5.0 (San Diego, CA, USA), with data presented 16 
as mean ± SEM. Comparative analyses between groups were carried out using Student’s 17 
unpaired t-test, one-way ANOVA with a Bonferroni post hoc test, or a two-way repeated 18 
measures ANOVA with a Bonferroni post hoc test where appropriate. Results were deemed 19 






























Insulin secretion and cell viability following PPPH co-incubation with BRIN-
BD11 cells  
Insulin secretion was determined over a 20 min co-incubation with PPPH supplemented 
glucose. Baseline insulin secretion was established utilising KRBB buffer supplemented with 
basal 5.6 mM or elevated 16.7 mM glucose. Several PPPH’s, subjected to different hydrolysis 
conditions, were employed along with SGID equivalents over an identical concentration range 
(0.0195–2.5 mg/ml). Aqueous/alkaline protein isolate which was subjected to similar 
hydrolysis condition to that of PPPH’s, albeit without the addition of enzyme, was employed 
as a control and elicited elevated (p<0.01 - p<0.001) insulin secretion at 1.25 and 2.5 mg/ml 
at basal glucose concentration (Fig. 1A). Interestingly, its SGID equivalent presented 
with surprisingly high insulinotropic activity (p<0.01-p<0.001 at > 0.312 mg/ml) when 
tested at 16.7 mM glucose concentration in BRIN-BD11 cells (Fig. 1B). While potentially 
anomalous, improved potency (p<0.01-p<0.001 at > 0.156 mg/ml) following SGID 
highlights the importance of more complete hydrolysis to the insulinotropic effect. 
The inverse was true for PPPH’s. Alcalase PPPH stimulated insulin secretion (p<0.001) 
from 0.312 mg/ml and above (Fig. 1C). However, following SGID, the effect on insulinotropic 
potency was negatively impacted, with bioactivity (p<0.05 to p<0.01) observed from 1.25 
mg/ml and above (Fig. 1D). Alteration of the hydrolysis medium for Alcalase/Flavourzyme 
PPPH improved potency, with augmented (p<0.01 to p<0.001) insulin secretion from 0.312 
mg/ml and above (Fig. 1E). Post-SGID, Alcalase/Flavourzyme PPPH displayed improved 
potency, increasing (p<0.001) insulin secretion at 0.625 mg/ml or above (Fig. 1F). Of other 
digestion conditions, the bromelain PPPH exhibited promising insulin secretory actions, with 
improvements (p<0.05 - p<0.001) compared to baseline at 0.078 mg/ml or above (Fig. 1G). 25 
14 
SGID negatively impacted efficacy; however, potency was still impressive, enhancing 1 
(p<0.001) insulin secretion from 1.25 mg/ml or higher (Fig. 1H). Somewhat unexpectedly, the 2 
Promod PPPH (Fig. 1I) and its SGID equivalent (Fig. 1J) displayed bioactivity over an identical 3 
concentration range (0.625 - 2.5 mg/ml) with only the magnitude of the increased insulin 4 
secretion being slightly impacted following SGID.  5 
PPPH’s were further tested in the presence of 16.7 mM glucose. While potency was 6 
slightly altered, the magnitudes and trends involving SGID were largely the same for the 7 
aqueous, Alcalase, Alcalase/Flavourzyme PPPH’s and their SGID counterparts (Fig. 2A-F). 8 
The potency of both bromelain and Promod PPPH’s at elevated glucose was reduced, with 9 
respect to the 5.6 mM glucose data, but they retained a dose-dependent effect above 0.625 (Fig. 10 
2G,I).  SGID enhanced the potency of these PPPH’s in both cases (Fig. 2.H,J). Importantly, 11 
when tested at the highest concentration, cell viability was not negatively impacted by the 12 
inclusion of any PPPH at either 5.6 mM (Fig. 1K) or 16.7 mM glucose (Fig. 2K).  13 
14 
Preservation of the incretin effect 15 
16 
As shown in Table 1, DPP-4 inhibition significantly increased following digestion with all 17 
proteolytic enzymes employed. Greatest inhibition was observed with PPPH’s generated with 18 
Alcalase/Flavourzyme or Alcalase alone, achieving DPP-4 IC50 values of 0.70 ± 0.02 and 0.94 19 
± 0.10 mg/ml, respectively. Bromelain and Promod PPPH’s had lower DPP-4 inhibitory 20 
activity with IC50 values of 1.34 ± 0.05 and 1.23 ± 0.05, respectively. IC50 values of the control 21 
and PPPH’s were significantly altered by SGID. The DPP-4 inhibitory activity mediated by the 22 
control and bromelain and Promod PPPH’s increased (p<0.05) following SGID. In contrast, 23 
the DPP-4 inhibitory activity with Alcalase/Flavourzyme and Alcalase PPPH’s decreased 24 
15 
(p<0.05) following SGID. Thus, in the latter case peptides eliciting high DPP-4 inhibitory 1 
activity in the hydrolysate were degraded during SGID. 2 
3 
Promotion of the incretin effect 4 
5 
The effects of PPPH upon GLP-1 and GIP secretion was investigated via acute exposure 6 
of enteroendocrine GLUTag and STC-1 cell lines, respectively. Positive controls, glutamine 7 
(10 mM), forskolin (10 mM) and GIP (10-6 M) returned from 2- to 4-fold (p<0.05 - p<0.001) 8 
increases in GLP-1 secretion when compared to basal glucose (2 mM) control (Fig. 3A). 9 
Likewise, palmitic acid (500 M) and glutamine (10 mM) showed a 4-fold increase (p<0.001) 10 
in GIP secretion compared to glucose control (Fig. 3B). PPPH’s (2.5 mg/ml) were subsequently 11 
co-incubated with 2 mM glucose to investigate their effects on hormone secretion.  12 
The aqueous/alkaline protein control elicited a 3-fold increase (p<0.001) in GLP-1 13 
secretion compared to basal glucose control (Fig. 3A). Following SGID, bioactivity was 14 
reduced (p<0.05); however, GLP-1 secretion remained elevated (p< 0.01) versus the 2 mM 15 
glucose control (Fig. 3A). Interestingly, the inverse was true for GIP secretion, where the 16 
protein control elicited a 4-fold (p<0.001) increase, but the SGID equivalent led to 5.8-fold 17 
(p<0.001) increase in GIP secretion compared to glucose control (Fig. 3B). Alcalase PPPH 18 
displayed a 2-fold (p<0.001) increase in GLP-1 secretion, but post-SGID it failed to raise 19 
secretion beyond the glucose control (Fig. 3A). For GIP secretion, Alcalase PPPH resulted in 20 
a 6-fold (p<0.001) increase which was improved post SGID, with an 8-fold (p<0.001) 21 
upregulation (Fig. 3B). Little change was observed following addition of Flavourzyme, with 22 
the hydrolysate promoting a 2.2-fold increase in GLP-1 secretion (p<0.001) accompanied by a 23 
loss of bioactivity following SGID (Fig. 3A). Unexpectedly, GIP secretion was impacted by 24 
16 
Alcalase/Flavourzyme digestion, whereby the secretory activity was mildly elevated (1.2-fold; 1 
p<0.01); however, following SGID, a significant reduction (p<0.01) in secretion was observed 2 
(Fig. 3B). Bromelain PPPH produced 2-fold (p<0.001) rise in GLP-1 secretion but only 3 
retained a 1.4-fold (p<0.05) secretory response post SGID (Fig. 3A). Bromelain PPPH and its 4 
SGID counterpart increased GIP secretion 5-fold (p<0.001) and 3.5-fold (p<0.001), 5 
respectively, retaining relatively high bioactivity post SGID (Fig. 3B). The same was largely 6 
true for Promod PPPH, displaying a 1.6-fold (p<0.001) increase in GLP-1 secretion which was 7 
reduced to 1.4-fold (p<0.05) following SGID (Fig. 3A). Again, GIP secretion was relatively 8 
well-retained with 6-fold (p<0.001) and 3.8-fold (p<0.001) improvements in hormone 9 
secretion beyond control culture for Promod PPPH and its SGID equivalent, respectively (Fig. 10 
3B).  11 
12 
Mechanistic consequences of co-incubation with PPPH 13 
The cellular consequences following co-incubation of 2.5 mg/ml of PPPH were investigated in 14 
BRIN-BD11 cells supplemented with 5.6 mM glucose. Specifically, cyclic adenosine 15 
monophosphate (cAMP), intracellular calcium ([Ca2+]i) and membrane potential were tested 16 
under identical conditions. cAMP was initially used to screen PPPH’s. The positive controls, 17 
16.7 mM glucose and GLP-1 (10-6 M), elevated (p<0.05 and p<0.001, respectively) 18 
intracellular cAMP versus 5.6 mM glucose control (Fig. 4A). All six non-SGID, PPPH’s raised 19 
cAMP production (p<0.05 - p<0.001) in BRIN-BD11 cells (Fig. 4A), while only SGID, 20 
Alcalase and SGID, Promod PPPH’s failed to stimulate cAMP above the 5.6 mM control (Fig. 21 
4A). Notably, Alcalase/Flavourzyme PPPH and its SGID counterpart, elicited the greatest rise 22 
in intracellular cAMP, upregulating 1.7-fold (p<0.001) compared to 5.6 mM glucose control 23 
(Fig. 4A). As a result of constraints over assay availability, combined with the limited 24 
17 
availability of SGID sample, only Alcalase/Flavourzyme PPPH was investigated further with 1 
respect to cellular signalling.  2 
In terms of intracellular Ca2+ mobilisation, the positive control, alanine (10 mM), elicited 3 
a 15-fold increase (p<0.001) in calcium mobilisation compared to the 5.6 mM glucose control 4 
culture (Fig. 4B,C). Alcalase/Flavourzyme PPPH greatly surpassed (p<0.001) the positive 5 
control, increasing Ca2+ mobilisation 80-fold (p<0.001) versus the 5.6 mM glucose control 6 
(Fig. 4B,C). With respect to membrane potential, potassium chloride (KCl, 30 mM) a potent 7 
membrane potentiating insulinotropic electrolyte, caused a 75-fold increase (p<0.001) in 8 
membrane potential during acute co-incubation with 5.6 mM glucose (Fig. 4D,E). Further to 9 
increased Ca2+, Alcalase/Flavourzyme PPPH returned a 125-fold peak increase (p<0.001) in 10 
membrane potential versus 5.6 mM glucose control in BRIN-BD11 cells (Fig. 4D,E).  11 
12 
Effects of PPPH on in vitro glucose uptake 13 
The 3T3-L1 cell line was investigated following trans-differentiation from fibroblast to 14 
adipocyte cells. Apigenin control culture evoked a significant reduction (p<0.001) of glucose 15 
uptake, via the inhibition of the GLUT-1 receptor, with the inverse for low (1 nM) and high 16 
(100 nM) insulin, causing 1.4- and 1.8-fold increases (p<0.001) in glucose uptake, respectively 17 
(Fig. 5A). All PPPH’s and their SGID equivalents, were employed either alone at 2.5 mg/ml 18 
or in combination with basal insulin (1 nM).  19 
Interestingly, while the protein control failed to show a significant increase in glucose on 20 
its own, in the presence of insulin a 1.5-fold increase (p<0.05) was observed (Fig. 5B). The 21 
inverse was true following SGID causing significantly increased (p<0.05) glucose uptake on 22 
its own, with surprising loss of effect in the presence of insulin (Fig. 5B). When co-incubated 23 
alone, Alcalase PPPH and its SGID equivalent both caused comparable, 1.5-fold (p<0.001), 24 
18 
increases in glucose uptake; however, when co-incubated with insulin, no additive effect was 1 
displayed (Fig. 5C). Alcalase/Flavourzyme PPPH, when incubated alone, caused a 1.8-fold 2 
increase (p<0.001) in glucose uptake, with co-incubation with insulin not impacting greatly, 3 
demonstrating a 1.7-fold increase (p<0.001) in uptake (Fig. 5D). Similarly, post-SGID, elicited 4 
a 1.38-fold (p<0.05) rise in glucose uptake both with and without insulin present (Fig. 5D). 5 
Bromelain PPPH failed to improve glucose uptake when incubated on its own, with notable 6 
improvement presented as a 1.5-fold increase (p<0.01) following insulin co-incubation (Fig. 7 
5E). However, following SGID, the sample failed to produce an improvement in glucose 8 
uptake in the absence or presence of insulin (Fig. 5E). Similarly, Promod PPPH was only 9 
effective in the presence of insulin, when glucose uptake increased by 1.5-fold (p<0.05), but 10 
this was lost following SGID, with the sample having no effect either alone or in the presence 11 
of insulin (Fig. 5F).  12 
13 
Acute in vivo effects following oral administration of PPPH 14 
Following initial dose-response investigations (see Supplementary Figures), a 100 mg/kg/bw 15 
dose of Alcalase/Flavourzyme PPPH was employed for in vivo investigations. When co-16 
administered with 18.8 mM glucose, PPPH significantly curbed rises in blood glucose at 60 17 
min (p<0.01), as well as 90 and 120 min (p<0.001), when compared to glucose-only control 18 
(Fig. 6A). Additionally, the area under the curve (AUC) was significantly reduced (p<0.01) 19 
compared to control (Fig. 6B). Positive glycaemic effects appear to be relatively short-lasting, 20 
with a delayed oral glucose challenge showing no anti-hyperglycaemic efficacy when delivered 21 
4, 8 or 12 h post PPPH administration (data not shown).  22 
19 
Additionally, when co-administered with saline, PPPH (100 mg/kg) demonstrated 1 
significant reductions (p<0.05 to p<0.001) in food intake (16-20% from 90 to 180 min) when 2 
tested in diet-restricted animals (Fig. 6C).  3 
4 
Discussion 5 
While accepted that an increase in dietary protein intake can have positive effects on glycaemic 6 
control for T2DM patients [10]; expanding population sizes, coupled with pre-existing social 7 
inequality, continue to drive global protein malnutrition [45-47]. It is predicted that the global 8 
human population will reach 9 billion by 2050, meaning trends in population expansion are 9 
unlikely to be curbed. Thus, greater emphasis must be placed on ensuring food security [48]. 10 
Novel sources are being pursued to address this, one such being the exploration of marine 11 
sources like seaweeds, industry off-cuts and underutilised, or low value fish species, many of 12 
which are currently used as animal and farmed fish/shellfish feed [31,49,50]. Algal proteins 13 
are of particular interest due to a favourable amino acid composition, containing all nine 14 
essential amino acids [51], combined with a relatively high protein content, particularly for red 15 
seaweeds which often contain ≥30% of protein by dry weight [52].  16 
It was recently established that chronic administration of an Alcalase/Flavourzyme PPPH 17 
can improve glycaemic control in STZ-induced diabetic mice [34]. Therefore, utilising an array 18 
of in vitro and acute in vivo techniques, the present study aimed to uncover causative 19 
mechanisms of PPPH-induced benefits in diabetes, investigating Alcalase/Flavourzyme PPPH 20 
while taking the opportunity to compare it to a number of other enzymatically produced 21 
PPPH’s.  22 
Initial screening involved assessment of insulinotropic activity of PPPH’s in BRIN-23 


























protein hydrolysates [25-27]. We hypothesised that activity would rely on the hydrolysis 
process, specifically the duration of hydrolysis and the protease used, ultimately leading to a 
different range of bioactive peptides within crude mixtures [53]. Our data appears to support 
this, particularly with respect to the choice of enzyme and the extent to which it hydrolyses P. 
palmata proteins and the MW of peptides therein. As reflected in the molecular distribution 
profiles (Supplementary Table 1), and accompanying GP-HPLC profiles (Supplementary Fig. 
4), both Alcalase and Alcalase/Flavourzyme mediated a higher extent of hydrolysis of P. 
palmata proteins than bromelain and Promod. Also, all hydrolysates were further hydrolysed 
during the in vitro digestion process, which had either a positive or negative impact on 
bioactivity.  
Insulinotropic effects of the protein control, were vastly improved following SGID, while 
the insulinotropic potency of Alcalase and Alcalase/Flavourzyme PPPH’s subjected to SGID 
was reduced rather than totally abolished, an encouraging finding. Intriguingly, particularly at 
16.7 mM glucose, bromelain and Promod PPPH’s showed unaltered or even improved 
bioactivity post SGID. Further analysis may uncover the possibility that glycation of specific 
components can affect their bioactivity, with the data suggesting that, for most PPPH’s, the 
potency of insulinotropic effect was greater at 16.7 mM than at 5.6 mM glucose.  Given 
insulinotropic peptides, such as GIP, are demonstrated to have improved bioactivity following 
N-terminal glycation [54,55], this may be plausible, but remains a hypothesis. Furthermore, 
the favourable MTT data showing no cellular cytotoxicity, demonstrated that the increased 
insulin release induced by PPPH was not a result of beta-cell lysis [56].   
It is well established that both crude hydrolysates [32], and isolated peptide sequences 
[33], derived from P. palmata, have excellent DPP-4 inhibitory properties. As such, for the 
present set of PPPH’s, these findings have been corroborated. Furthermore, the effects were 


























bioavailability [25,27]. While likely a less important factor in in vitro insulin secretion than in 
in vivo scenarios, previously identified presence of intra-islet DPP-4 [73], as well as 
expression within beta-cells themselves [74], means the influence of DPP-4 inhibitory 
effects to the insulinotropic effects of PPPH’s cannot be completely ruled out, but certainly 
warrant further investigation. The clinical success of DPP-4 inhibition is mediated through 
preservation of the incretin effect, and this mechanism is well established in management of 
T2DM [23,57-59]. The present data demonstrates that: beyond preservation of the incretin-
effect, crude PPPH’s can directly influence incretin-mediated glycaemic improvements via 
the stimulation of GLP-1 and GIP secretion [60]. Thus, all PPPH’s enhanced both in vitro 
GLP-1 and GIP secretion in their unaltered states, a finding supported by previous findings of 
marine protein-hydrolysate-induced GLP-1 secretion [25,27]. Intriguingly, the effects on GIP 
secretion were more resistant to SGID than those of GLP-1, with the effect at least retained 
for every hydrolysate except Alcalase/Flavourzyme PPPH. It is important to note that, 
given the crude nature of the hydrolysate mixtures, differing small MW peptides or free 
amino acid components may be responsible for each effect.  
In vitro analysis of mechanistic consequences of PPPH co-incubation further highlight 
the ability of PPPH to influence insulin release. Membrane depolarisation, calcium 
mobilisation and generation of cAMP were employed to provide a general overview of activity. 
As such, cAMP upregulation suggests that small MW peptides may be stimulating secretion of 
hormones such as insulin, GLP-1 and GIP via G-coupled protein receptor activation [61]. These 
receptors are only activated by extracellular stimuli and can have potent cellular activation via 
promotion of internal signalling cascades [62,63].  For example, activation of the GLP-1r via 
GLP-1 promotes a significant increase in cAMP production and glucose dependent insulin 
secretion [63]. Indeed, each PPPH elicited cAMP elevation beyond baseline, with varying 
degrees of effect. In particular, Alcalase/Flavourzyme PPPH exhibited the most potent 25 
22 
elevation, with full retention following SGID. Furthermore, this hydrolysate greatly influenced 1 
both membrane depolarisation and calcium mobilisation, beyond positive controls. While the 2 
direct effects on intracellular signalling appear to be multifaceted [62-64], further investigation 3 
is required to identify whether the bioactivity emanates from a potent singular peptide entity 4 
within the crude mixture, or if it arises from synergistic mechanisms of various peptides or 5 
amino acids [65].  6 
3T3-L1 adipocyte cells were utilised to examine the ability of the PPPH and SGID 7 
samples to stimulate glucose uptake. These cells exhibit all the components of insulin receptor 8 
and signal transduction cascade and are frequently used to investigate insulin mediated glucose 9 
transport [66]. It is believed that compensatory upregulation of insulin production and secretion 10 
can result in impaired glucose transport into liver, skeletal muscle, and adipose tissue in T2DM 11 
[67]. Furthermore, it is postulated that dysfunctional peripheral glucose uptake, may contribute 12 
to insulin resistance in skeletal muscle [68]. The present data unveils a positive role for PPPH 13 
in glucose transport, with Alcalase and Alcalase/Flavourzyme PPPH’s increasing glucose 14 
uptake, independent of insulin, with the effect partially surviving SGID. Such findings may be 15 
related to the acute glucose tolerance test data. Thus, oral administration of 16 
Alcalase/Flavourzyme PPPH improved the oral glucose tolerance significantly from 60 min 17 
onwards of challenge initiation. While thought to be multifactorial in nature, improved glucose 18 
uptake could be a contributing factor [69]. Insulin determination was not possible during these 19 
experiments; however, previous findings have demonstrated that chronic administration of an 20 
equivalent dose of this hydrolysate (split into twice daily 50 mg/kg/bw dosage) improved non-21 
fasting insulin levels, with accompanying improvements in circulating glucose and HbA1c, over 22 
the treatment period [34]. Additionally, we highlight a role for PPPH administration in satiety, 23 
with notable reduction from baseline evident from 90-180 min inclusive when tested in food 24 

























Taken together, this dataset fortifies interest in PPPH with regards to management of 
T2DM. Knowledge of the previously established roles in DPP-4 inhibition [32] and partial 
reversal of STZ-induced diabetes [34] have been expanded upon. Here, we show clear roles for 
PPPH in direct insulin and incretin secretion, supported by cellular signalling data, as well as 
improvements in glucose utilisation and tolerance now identified. Given it is now accepted 
that particular combinations of individual amino acids, such as leucine, alanine and 
glutamine, at supraphysiological concentrations can augment insulin secretion [72], we 
postulate that such a mechanism may be at play here with crude hydrolysate mixtures, thus 
future work may isolate, identify and characterise specific peptides, single amino acids or 
combinations thereof, small molecules or lipids from the most consistently 
promising of the hydrolysates, Alcalase/Flavourzyme PPPH [33]. This hydrolysate was 
particularly promising given its direct insulinotropic effects, accompanied by promising 
effects on the intracellular mechanisms linked to insulin release, along with positive effects 
on glucose uptake.  
The study possesses some limitations, primarily that limited SGID sample availability 
did not permit inclusion of all test hydrolysates in our mechanistic investigations.  In the 
present preliminary study, the findings observed herein on glycaemic control and insulin 
secretion could arise due to multiple different actions mediated by the PPPH peptides. 
These might involve for example, the inhibition of DPP-4 prolonging the bioactivity of 
GLP-1 and GIP incretin hormones or insulinotropic actions of free amino acids. However, 
extensive detailed mechanistic studies would be required to elucidate the various 
mechanisms, which is beyond the scope of the current study.  Furthermore, a chronic study 
with isolated peptides would be warranted to increase our knowledge on the bioactivity 
residing in PPPH. Additionally, given all the hydrolysates assessed herein inhibit 
angiotensin converting enzyme (ACE) (data not shown) combined with our clearly 
identified effects on satiety, it may be interesting to 
24 
24 
investigate the influence PPPH can play on regulation of satiating hormones like 1 
cholecystokinin (CCK) and PYY(3-36), both of which are substrates for ACE [70,71]. 2 
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Figure Legends 1 
2 
Figure 1. (A-J) Effects of PPPH (0.0195 – 2.5 mg/ml) on insulin release from clonal pancreatic 3 
BRIN-BD11 beta-cells at basal, 5.6 mM, glucose concentration. (K) Additionally, effects of a 4 
fixed (2.5 mg/ml) concentration of various protein hydrolysate on cell viability were also 5 
investigated. Values are mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 compared to 6 
control 5.6 mM glucose (A-K). Con: aqueous/alkaline control, AF: Alcalase/Flavourzyme, 7 
Alc: Alcalase, Brom: Bromelain, Prom: Promod. 8 
9 
Figure 2. (A-J) Effects of PPPH (0.0195–2.5 mg/mL) on insulin release from clonal pancreatic 10 
BRIN-BD11 beta-cells at elevated, 16.7 mM, glucose concentration. (K) Additionally, effects 11 
of a fixed (2.5 mg/ml) concentration of various protein hydrolysate on cell viability were also 12 
investigated (K). Values are mean ± SEM (n=8). **p<0.01, ***p<0.001 compared to control 13 
16.7 mM glucose (A-K). Con: aqueous/alkaline control, AF: Alcalase/Flavourzyme, Alc: 14 
Alcalase, Brom: Bromelain, Prom: Promod. 15 
16 
Figure 3. Effects of fixed concentration (2.5 mg/mL) of PPPH on the incretin effect through 17 
(A) GLP-1 release from GLUTag cells and (B) GIP release from STC-1 α-cells. Values are18 
mean ± SEM (n=4). p<0.05, **p<0.01, ***p<0.001 compared to 2 mM glucose controls (A,B). 19 
Δp<0.05, ΔΔp<0.01, ΔΔΔp<0.001 compared to the appropriate, non-SGID hydrolysate (A,B). 20 
Con: aqueous/alkaline control, AF: Alcalase/Flavourzyme, Alc: Alcalase, Brom: Bromelain, 21 


























Figure 4. Mechanistic effects of coincubation with fixed concentration (2.5 mg/ml) of PPPH 
following 20 min incubation with BRIN-BD11 cells. (A) PPPH’s and SGID equivalents, 
were tested for influence on cAMP concentration, (B) while only the Alcalase/Flavourzyme 
PPPH (AF) was employed for the study of intracellular calcium mobilisation and (D) 
membrane potential. Respective AUC values are also provided (C,E). Values are mean ± 
SEM (n=3). 
*p<0.05, **p<0.01, ***p<0.001 compared to 5.6 mM glucose control (A,C,E). ΔΔΔp<0.001
compared to the 10 mM alanine positive control (C,E). Con: aqueous/alkaline control, AF: 
Alcalase/Flavourzyme, Alc: Alcalase, Brom: Bromelain, Prom: Promod. 
Figure 5. Effects of PPPH (2.5 mg/ml) on glucose uptake individually, or in combination 
with insulin (1 nM), in trans-differentiated 3T3-L1 adipocyte cells. Responsiveness of 
adipocyte cells was assessed via incubation with either apigenin (50 M), insulin (1 nM or 
100 nM) (A). Adipocyte cells were further incubated with either Con/Con-SGID (B), Alc/
Alc-SGID (C), AF/AF-SGID (D), Brom/Brom-SGID (E) or Prom/Prom-SGID (F) using 
fixed concentration of hydrolysate (2.5 mg/ml) for 1 h with 3 mM fluorescent glucose (2-
NBDG). Values are mean ± SEM (n=3). *p<0.05, **p<0.01, ***p<0.001 compared to 
respective glucose control. Con: aqueous/alkaline control, AF: Alcalase/Flavourzyme, Alc: 
Alcalase, Brom: bromelain, Prom: Promod. 
Figure 6. (A,B) Effects of a fixed dose (100 mg/kg/bw) of  Alcalase/Flavourzyme PPPH 
(AF) on glucose tolerance in lean, overnight-fasted (16 h) NIH Swiss mice and (C) acute food 
intake in lean, diet-restricted HsD:Ola T0 mice. Animals (n=8) received glucose (18.8 mmol/
kg/bw) alone or in combination with hydrolysate (A) or saline (0.9% NaCl) alone or in 
combination with hydrolysate via oral gavage (C). Measurements were taken at regular 
intervals as indicated 
24 
38 
(A,C). Values are mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 compared to glucose 1 





























































































































































































































































































































































































































































































































































































































5.6 mM Glucose + PPPH



























5.6 mM Glucose + PPPH SGID








































































































































































































































































































































































































































































































































































16.7 mM Glucose + 1 mM H2O2





















16.7 mM Glucose + PPPH SGID



































































































2 mM Glucose + 10 mM Glutamine
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2 mM Glucose + 500 M Palmitic Acid
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5.6 mM Glucose + 10 mM Alanine
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Table 1. DPP-4 inhibitory activity of PPPH’s and their SGID equivalents 
IC50 value (mg/ml)
Proteolytic activity PPPH PPPH-SGID 
Control (none) 1.91 ± 0.10d 1.09 ± 0.06bc  * 
Alcalase + Flavourzyme 0.70 ± 0.02a 1.00 ± 0.03bc  * 
Alcalase 0.94 ± 0.10b 1.14 ± 0.05c    * 
Bromelain 1.34 ± 0.05c 0.95 ± 0.08b    * 
Promod 1.23 ± 0.05c 0.78 ± 0.02a   * 
Mean ± SD (n=3), IC50: inhibitory concentration that inhibits enzyme activity by 50%. * indicates a significant 
difference (p< 0.05) in IC50 values following SGID. 
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